Myrexis

Myrexis is a biopharmaceutical company based in Salt Lake City, Utah, USA. It focused on drug development in several areas of medicine, in particular cancer therapy and auto-immune diseases. It was founded in 1999 as a spin-off from Myriad Genetics^[1] and was originally known as Myriad Pharmaceuticals. Richard B. Brewer was its CEO from May 2012 until his death in August 2012.^[2]^[3]

In February 2012 the company announced they had suspended development activity on all of its clinical and preclinical programs and appointed an investment company Stifel Nicolaus Weisel to evaluate strategic alternatives.^[4] In November 2012, the board of Myrexis announced that it planned to put the company into liquidation subject to shareholder approval.^[5] In January 2013, the board reversed its decision, cancelled the liquidation, declared a special cash distribution to shareholders and appointed Jonathan M. Couchman (chairman of Xselos Holdings) as president and chief executive officer. The remaining members of the board then resigned.^[6]

References

^ Staff (2 July 2009) "Myriad Pharmaceuticals, Inc. Established As An Independent Pharmaceutical Development Company" Pharmaceutical Online, 2 July 2009. Retrieved 26 July 2014
^ "Richard Brewer". San Francisco Chronicle. 20 August 2012. Retrieved 25 August 2012.
^ "Myrexis Announces Death of Chief Executive Officer Richard B. Brewer, Trailblazing Biotechnology Industry Veteran and Patient Advocate". Myrexis. Archived from the original on November 5, 2012. Retrieved 15 August 2012.
^ Staff. "MYRX.PK - Myrexis Inc Profile | Reuters". Reuters. Retrieved 2021-02-05.^{[dead link]}
^ Tadena, Nathalie, "Myrexis Board Approves Plan to Liquidate Assets, Dissolve Company", The Wall Street Journal, 9 November 2012. Retrieved 20 January 2013 ^{[dead link]}
^ Myrexis Inc press release:"Myrexis, Inc. Announces the Cancellation of Its Upcoming Shareholder Meeting", carried by Bloomberg, 23 January 2013. Retrieved 26 July 2014

[1] Staff (2 July 2009) "Myriad Pharmaceuticals, Inc. Established As An Independent Pharmaceutical Development Company" Pharmaceutical Online, 2 July 2009. Retrieved 26 July 2014

[obit-2] "Richard Brewer". San Francisco Chronicle. 20 August 2012. Retrieved 25 August 2012.

[myrexis-3] "Myrexis Announces Death of Chief Executive Officer Richard B. Brewer, Trailblazing Biotechnology Industry Veteran and Patient Advocate". Myrexis. Archived from the original on November 5, 2012. Retrieved 15 August 2012.

[4] Staff. "MYRX.PK - Myrexis Inc Profile | Reuters". Reuters. Retrieved 2021-02-05.^{[dead link]}

[5] Tadena, Nathalie, "Myrexis Board Approves Plan to Liquidate Assets, Dissolve Company", The Wall Street Journal, 9 November 2012. Retrieved 20 January 2013 ^{[dead link]}

[6] Myrexis Inc press release:"Myrexis, Inc. Announces the Cancellation of Its Upcoming Shareholder Meeting", carried by Bloomberg, 23 January 2013. Retrieved 26 July 2014

[1]

[2]

[3]

[4]

[5]

[6]